Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin...

Area of Science:

• Cardiology
• Preventive Medicine
• Biomarkers

Background:

• Clinical guidelines recommend statin therapy for individuals at high absolute risk of atherosclerotic cardiovascular disease (CVD).
• Accurate risk stratification is crucial for effective dyslipidemia management and primary prevention.

Purpose of the Study:

• To evaluate the role of coronary artery calcium (CAC) scoring in refining CVD risk assessment among individuals with varying lipid abnormalities.
• To determine if CAC scores can improve the allocation of statin therapy based on absolute CVD risk.

Main Methods:

• Analysis of 5534 Multi-Ethnic Study of Atherosclerosis (MESA) participants without baseline dyslipidemia medication.
• Classification based on coronary artery calcium (CAC) scores (>0, ≥100) and lipid abnormalities (LA).
• Longitudinal assessment of incident CVD events over a median follow-up of 7.6 years.

Main Results:

• Over half (55%) of CVD events occurred in 21% of participants with CAC ≥ 100.
• 65% of events occurred in participants with 0 or 1 lipid abnormality.
• Individuals with CAC ≥ 100 exhibited elevated CVD rates (22.7–29.5 per 1000 person-years) regardless of lipid abnormalities, with rates comparable to secondary prevention populations.

Conclusions:

• Coronary artery calcium (CAC) scoring demonstrates potential in optimizing statin therapy allocation by identifying individuals at high absolute CVD risk.
• CAC scores provide valuable risk information across the spectrum of dyslipidemia, aiding in personalized cardiovascular risk management.